MedPath

Proteom analysis in Serum of pediatric hemato-oncological patients with invasive aspergillosis

Conditions
B44.7
Disseminated aspergillosis
Registration Number
DRKS00031416
Lead Sponsor
Institut für medizinische Mikrobiologie und Hygiene, Universitätsklinikum Freiburg
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
60
Inclusion Criteria

hematooncologic primary disease
retained serumsamples with detection of galactomannan
informed consent given

Exclusion Criteria

other kind of immunosuppression
therapy with PLASMA-LYTE™ in a timeframe of four weeks to when the serumsample was taken
no retained serum samples available
no informed consent given

Study & Design

Study Type
observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Proteomanalysis of retained serum-samples of the patient collctive at timepoints before and at the time of galactomannan-detection as well as serum-samples of the controll-collektives by mass-spectrometry.
Secondary Outcome Measures
NameTimeMethod
Analysis of serumprotein-expressionlevels and clinical data for identification of potential biomarkers of invasive aspergillosis.
© Copyright 2025. All Rights Reserved by MedPath